TSOVINAR TEKKELIAN: Open Payments
NPI 1558447607 · GLENDALE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,687 in 67 payments from 20 companies in 2025. Trend: 2023 $1,977 · 2024 $1,723 · 2025 $1,687
Food & beverage: $1,687
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $228 |
| Ardelyx, Inc. | 8 | $227 |
| Amgen Inc. | 8 | $209 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $122 |
| Aimmune Therapeutics, Inc. | 4 | $114 |
| Novo Nordisk Inc | 5 | $105 |
| Lundbeck LLC | 4 | $101 |
| Novartis Pharmaceuticals Corporation | 4 | $93 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
Products named: IBSRELA, REXULTI, CAPLYTA, EVENITY, ZENPEP, Ozempic, LINZESS, LEQVIO.
Industry payments across CA — which companies pay providers there.
